Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
DaVita Inc. (NYSE: DVA) reported strong financial results for Q4 2024. Consolidated revenues reached $3.295 billion for Q4 and $12.816 billion for the full year. The company achieved operating income of $565 million and adjusted operating income of $491 million in Q4, with full-year figures of $2.090 billion and $1.981 billion respectively.
Q4 diluted earnings per share was $3.09, with adjusted EPS at $2.24. Operating cash flow stood at $548 million with free cash flow of $281 million for the quarter. The company actively engaged in share repurchases, buying back 2.3 million shares at an average price of $156.46 per share in Q4.
DaVita provided dialysis services to approximately 281,100 patients across 3,166 outpatient centers globally, with 2,657 centers in the US and 509 centers across 13 other countries. However, U.S. dialysis treatments showed a per-day decrease of 1.4% compared to Q3 2024.
DaVita Inc. (NYSE: DVA) has announced its upcoming fourth quarter 2024 investor conference call, scheduled for Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company will release its financial results after the market closes on the same day.
The conference call will be accessible via webcast through DaVita's IR web page. Participants can join through the provided webcast link or by calling 877-918-6630 (domestic) or 517-308-9042 (international). Callers must provide the password 'Earnings' along with their name and company affiliation.
While a webcast replay will be available on investors.davita.com for those unable to attend the live call, there will be no telephone replay option available.
DaVita marks its 25th anniversary of kidney care excellence, highlighting significant achievements in healthcare innovation and patient care since 2000. The company reports notable progress in 2024, including a record-breaking 8,200 patient kidney transplants and 15% of patients receiving home dialysis treatment.
Key accomplishments include rapid disaster response during Hurricanes Helene and Milton, expanding global operations to 14 countries including new presence in Chile, Ecuador, and Japan, and achieving 100% implementation of the BREEZE platform for streamlined health information exchange. The company has strengthened its partnership with the American Diabetes Association to advance chronic disease prevention and expanded its DaVita Health Tour providing free health screenings.
DaVita's commitment to sustainability is demonstrated through its progress toward 100% renewable energy usage globally, following its achievement of this goal in the U.S. in 2021. The company has received recognition from major publications including USA Today, Newsweek, and TIME as a leading employer and force for good.
DaVita has activated its emergency response plan due to Southern California wildfires, implementing measures to ensure continuity of care for dialysis patients. The plan includes patient and employee accounting, facility assessment, patient transfers to safe centers, medical information coordination, and air scrubber installation in affected areas.
The company is maintaining operations where possible and coordinating with other healthcare providers to ensure uninterrupted dialysis treatment. With over 80,000 Californians requiring dialysis treatment, DaVita has established a helpline (1-800-400-8331) for patients to locate open centers.
The company also provides guidance for kidney patients' emergency preparedness, recommending an emergency kit containing essential items such as contact numbers, medications for at least three days, diabetes supplies if needed, and emergency food supplies.
DaVita announced record-breaking participation in its third annual Move It With Purpose (MIWP) event, with over 8,300 participants logging 550,000 miles of activity across nearly 150 events nationwide. The month-long initiative raised more than $750,000 for Bridge of Life, DaVita's nonprofit organization focused on global chronic disease prevention and treatment.
Since 2007, DaVita's fundraising events have generated over $15 million for Bridge of Life, which has reached 34 countries and impacted nearly 150,000 lives through its 3,000 volunteers. The organization provides screenings, medications, and education in countries including Bangladesh, Belize, Guatemala, South Africa, and Vietnam.
DaVita Inc. (NYSE: DVA) announced its participation in the UBS Global Healthcare Conference 2024 on November 12, 2024. CFO Joel Ackerman and Group VP of Investor Relations Nic Eliason will engage in a fireside chat at 12:30 pm PST.
DaVita is a leading kidney care provider serving 265,400 patients across 3,113 outpatient dialysis centers globally, with 2,660 centers in the United States and 453 centers in 13 other countries as of September 30, 2024. The company specializes in comprehensive kidney care services, from disease progression management to transplantation support and home dialysis, maintaining a 20-year track record of clinical excellence and innovation.
DaVita Inc. (DVA) reported strong financial results for Q3 2024. The company achieved consolidated revenues of $3.264 billion and operating income of $535 million. Diluted earnings per share reached $2.50, while adjusted diluted EPS was $2.59. Operating cash flow was $810 million with free cash flow of $555 million.
The company repurchased 2.7 million shares at an average price of $147.20 per share. DaVita secured new financing through a $1.1 billion Term Loan A-1 and issued $1.0 billion in senior notes. U.S. dialysis metrics showed 7,350,784 total treatments, with revenue per treatment increasing to $394.49.
DaVita Giving Foundation announced an investment in the National Kidney Foundation's PEERS program, which provides social and emotional support for patients, care partners, and living donors through mentor connections. The program currently has over 356 participants as mentors and mentees, with 81% managing chronic illnesses like kidney failure.
The initiative aims to address mental health challenges in chronic disease care, as patients with chronic conditions are more likely to experience depression. The program facilitates telephone-based connections between participants, allowing them to discuss their kidney care journey with others who have similar experiences.
DaVita Clinical Research (DCR) will present five research projects at ASN's Kidney Week 2024 in San Diego. The research focuses on improving racial equity in transplantation and clinical quality measures. Studies examine topics including: the impact of nephrologist visits on hospitalization rates, racial disparities in transplant processes among Hispanic dialysis patients, effects of heavy precipitation on dialysis treatment attendance, early indicators of ESKD transition in AKI-dialysis patients, and blood pressure thresholds in CKD patients. The presentations aim to enhance upstream CKD care management and promote health equity.
DaVita announced performance year one clinical outcomes achieved through value-based care arrangements with nearly 1,300 nephrologists across the U.S. These efforts are part of the Comprehensive Kidney Care Contracting (CKCC) option within the government's voluntary Kidney Care Choices (KCC) model, which began on Jan. 1, 2022.
Key achievements include:
- 16% industry increase in optimal start rates for kidney patients transitioning to dialysis
- Embedding care team members in 68% of nephrology practices
- Overseeing approximately 31,000 patients across multiple care settings
- 2.4x more DaVita patients having a planned start on home treatment
- 67% of patients screened for depression remission
- 13% increase in patient activation
DaVita's tech-enabled platform and increased CKD education efforts have contributed to these improvements. The company expects continued progress in outcomes and cost savings as the CKCC program evolves.